New Scientific, Genetic and Clinical Insights into the Management of Triglycerides

This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines hypertriglyceridemia as a highly prevalent, yet modifiable, risk factor for pancreatitis, cardiovascular disease (CVD) and associated complications. Experts share the latest on triglyceride management including the safety, efficacy, and tolerability of pharmacologic agents alone and in combination with statins.

Opening Remarks
Chairperson:
Peter H. Jones, MD
Plasma Triglycerides and Risk for Coronary Heart Disease: What Does Human Genetics Teach Us?
Presenter:
Sekar Kathiresan, MD
The Pharmacologic Differences of TG-lowering Agents and Their Differential Effects on Components of Atherogenesis
Presenter:
R. Preston Mason, MBA, PhD
Selecting Appropriate Treatment Options for Patients With Hypertriglyceridemia
Presenter:
Howard S. Weintraub, MD
Panel Discussion - Selecting Appropriate Treatment Options for Patients With Hypertriglyceridemia
Moderator:
Peter H. Jones, MD
Discussants:
Sekar Kathiresan, MDR. Preston Mason, MBA, PhDHoward S. Weintraub, MD